Alx Oncology Holdings (ALXO) Depreciation & Amortization (CF) (2019 - 2026)

Alx Oncology Holdings has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $150000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 28.91% year-over-year to $150000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $645000.0 (down 25.78% YoY) and the FY2025 annual result came in at $706000.0, down 19.04% from the prior year.
• Depreciation & Amortization (CF) slipped to $150000.0 in Q1 2026 per ALXO's latest filing, from $151000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $224000.0 in Q3 2024 and troughed at $58000.0 in Q1 2022.
• A 5-year average of $170941.2 and a median of $207000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) surged 1483.33% in 2022, then sank 31.7% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $105000.0 in 2022, then jumped by 97.14% to $207000.0 in 2023, then rose by 3.38% to $214000.0 in 2024, then slipped by 29.44% to $151000.0 in 2025, then dropped by 0.66% to $150000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $150000.0, $151000.0, and $153000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.